Updates are available Correction dated 2019-01-29

Article History

Received: 21 December 2017

Accepted: 29 June 2018

First Online: 6 August 2018

Change Date: 29 January 2019

Change Type: Correction

Change Details: The original version of this Article contained an error in Fig. 2, in which the left <i>y</i>-axis labels ‘tDNA’ and ‘ctDNA’ were inadvertently inverted. This has been corrected in the PDF and HTML versions of the Article.

Competing interests

: The authors declare the following competing interests: Y.H.G., Y.F.G., X.Y., Y.T.Y., L.P.C., L.Y., Y.X.C., and T.L. are current employees of Geneplus-Beijing. X.Y. and L.Y. hold leadership positions and stocks of Geneplus-Beijing. J.V.H. is a consultant for AstraZeneca, Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Medivation, ARIAD, Synta, Oncomed, Novartis, Genentech, and Calithera Biosciences, holds stock in Cardinal Spine LLC and Bio-Tree, and has received funding from AstraZeneca. J.Z. is a consultant for AstraZeneca and receives honoraria from Bristol-Myers Squibb. I.I.W. receives honoraria from Roche/Genentech, Ventana, GlaxoSmithKline, Celgene, Bristol-Myers Squibb, Synta Pharmaceuticals, Boehringer Ingelheim, Medscape, Clovis, AstraZeneca, and Pfizer, and research support from Roche/Genentech, Oncoplex, and HGT. The remaining authors declare no competing interests.